Thalidomide-derived immunomodulatory drugs as therapeutic agents. - Wikidata - awgldk - TriplyDB

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

http://www.wikidata.org/entity/Q35967301

about

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Vaccines against human carcinomas: strategies to improve antitumor immune responses.Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.Chemotherapy for malignant glioma.Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).Small molecules and targeted therapies in distant metastatic disease.Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy Cost-effectiveness of lenalidomide in multiple myeloma.PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.AntiArthritis Therapies 2005.Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.Thalidomide Embryopathy: An Enigmatic Challenge

P2860

Q24605861-3B0935BA-06B5-4017-8A89-3132CEDD173A Q33734281-C016C853-0939-4E1C-B3B0-636A77AAA271 Q33947639-8058CDFF-4009-4132-A3A2-F316A84304B2 Q35609611-C9625E28-1847-4D50-AC5F-DD160E536C9F Q36307802-8741DA7A-EF09-4E2F-B4B4-8EBEFF91FAFF Q37330741-C783353B-E1C2-48B8-B0E2-AC2DEE070FE8 Q37555793-6E112DAB-293A-427D-BEFC-4C9BF7A9A56A Q37565960-10FD40D8-3E7F-4659-996E-392D93BCED0D Q37764870-C41B479D-1202-49FA-88F2-CF2E0FDAA27E Q37951937-54386DFC-888C-4A45-9137-FF8E6BDC9EE1 Q39463711-738E0C60-78AC-4EFF-9A49-C2B59CEFF6ED Q39627268-14F83167-FBF5-419F-9AF0-1765384D1CC6 Q46480280-9D831221-5708-458A-A235-6052B169F5F1 Q53073922-C9B1DAED-F162-429E-9FF2-9A7D9532293B Q57129133-9A414B9E-C11D-4895-AACB-149BCCEA55E6

P2860

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

http://www.wikidata.org/entity/Q35967301

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

@ast

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

@en

type

label

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

@ast

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

@en

prefLabel

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

@ast

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

@en

P1433

Q35967301-BE954121-2AEC-4228-9040-2B9CD8381E4D

P1476

Q35967301-FF0670F6-5035-4FA2-93CC-C4703AC79200

P2093

Q35967301-7332239D-4280-46FE-B1BD-16A4183D489F

Q35967301-AEEFA627-0D46-4CB7-8891-7C611D0E48C7

Q35967301-B5FB86C8-3831-48B5-A028-1470B63319AF

Q35967301-B8186549-62F3-4D41-A043-CCB8D5F2F2AF

P2860

Q35967301-15BB3333-A7E3-490F-A149-7F94F8666F53

Q35967301-1EAEBC9F-C44F-4079-8E4D-72B0FCB36906

Q35967301-23384160-7FFE-4886-9F4E-092F236752B6

Q35967301-2D280DD8-ABD3-427C-A7B6-35A23A58C8D1

Q35967301-2DFD826D-4D19-40B4-93B6-EB5BEAE7BF3C

Q35967301-3B99F643-2CD5-4F73-AC94-D753D2087D75

Q35967301-41D62997-BE00-436C-BBFD-FCA4AF72439C

Q35967301-425B0C27-1FBD-4223-8D87-A50132B0BCD6

Q35967301-4CD28EF2-EC08-4A73-AC37-D9CAA3302364

Q35967301-4D47932A-5551-4FE3-825B-2369F2C9D6C4

P304

Q35967301-4428CE6E-964A-4CD4-93BE-D8E09F3C25CE

P31

Q35967301-67D5581D-F738-459C-A9B0-6B4E07A0111E

P356

Q35967301-CD7F38E0-74E4-4A10-95A1-88F429F516B3

P407

Q35967301-A0305AEA-6A7B-4212-8068-42B320ED39A1

P433

Q35967301-A3AD345B-BBD7-4528-BAFB-2B57CEE2D1E7

P478

Q35967301-EF39175D-6015-4355-8A1B-BD0CC2B65BD5

P577

Q35967301-F8B933BB-F7EE-4C92-A03F-CCB6C3504C0C

P698

Q35967301-3C22D143-F9A1-455C-8CC5-D5BDD7F730B6

P921

Q35967301-BD0514ED-1F46-4574-B49B-B7C0F7CB86A3

P356

14712598.4.12.1963

P1433

Expert Opinion on Biological Therapy

P1476

Thalidomide-derived immunomodulatory drugs as therapeutic agents.

@en

P2093

Angus G Dalgleish

http://www.w3.org/2001/XMLSchema#string

Christine Galustian

http://www.w3.org/2001/XMLSchema#string

J Blake Bartlett

http://www.w3.org/2001/XMLSchema#string

Marie-Christine Labarthe

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide is an inhibitor of angiogenesis

Thalidomide and its analogues as cyclooxygenase inhibitors

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

The role of TNF in cardiovascular disease.

Antitumor activity of thalidomide in refractory multiple myeloma.

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

Thalidomide and immunomodulatory drugs as cancer therapy.

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor.

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

P304

1963-1970

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.4.12.1963

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2004-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15571458

http://www.w3.org/2001/XMLSchema#string

P921